656 results on '"Marc Bernard"'
Search Results
52. Liste des collaborateurs
- Author
-
Hssain, Ismaël, primary, Piedade, Isabelle, additional, Benveniste, Raphaëlle, additional, Marc, Bernard, additional, Miroux, Patrick, additional, Boraud, Cyril, additional, Braux, Hélène, additional, Broccoli, Christel, additional, Coutry, Loïc, additional, Crassus, Sandra, additional, Desmasures, Damien, additional, Bigara, Agnès Doherty, additional, Epain, Daniel, additional, Fetsch, Alexandra, additional, Garel, Alexia, additional, Grosser, Adeline, additional, Hanafy, Isis, additional, Hebincq, Anne-Sophie, additional, Jurkowski, Jérôme, additional, Koch, Pauline, additional, Leclerc, Johan, additional, Lefort, Hugues, additional, Lepetit, Frédéric, additional, Marc, Ghislaine, additional, Mazerand, Nadine, additional, Miran, Lydiane, additional, Rethaber, Linda, additional, Roulon, Anne-Laure, additional, Roux, Marie-Christine, additional, Sery, Alexandre, additional, Souaiby, Nagi, additional, Templier, François, additional, Verdis, Laetitia, additional, Villain, Johann, additional, Yahia, Yasmina, additional, Zerouki, Latifa, additional, Zumbiehl, Frédéric, additional, Jeleff, Charles, additional, Pateron., Dominique, additional, Andronikof, Marc, additional, Arabi, Miloud, additional, Arlie, Gilles, additional, Autret, Philippe, additional, Barrois, Jannick, additional, Barthélémy, Yolande, additional, Belkhodja, Omar, additional, Belle, Cindy, additional, Bellou, Abdel, additional, Bernot, Bruno, additional, Berton, Ludivine, additional, Biguet, Isabelle, additional, Bossard, Gwenaëlle, additional, Brakni, Hélène, additional, Cadiou, Loïc, additional, Cadot, Gilles, additional, Chassaignon, Cécile, additional, Coste, Geraldine, additional, Coudert, Benoît, additional, Daout, Muriel, additional, Debuc, Erwan, additional, Delaplace, Nadine, additional, Delfour, Françoise, additional, Deneux, Dominique, additional, Desandes, Céline, additional, Dib, Faiza, additional, Dorange, Karine, additional, Dulou, Lydie, additional, Dumont, Sylvie, additional, Dutertre, Sylviane, additional, François, Yannick, additional, Gicquel, Céline, additional, Grillot, Carole, additional, Hacquart, Betty, additional, Harant, Laurence, additional, Henry, Gaëtane, additional, Hinglais, Etienne, additional, Jullien, Claire, additional, Klein, Véronique, additional, Kizika, Muriel, additional, Klopp, Luce, additional, Légaut, Côme, additional, Letexier, Jean-Luc, additional, Letupe, Reine, additional, Liennard, Carine, additional, Mahieu, Catherine, additional, Manaouil, Cécile, additional, Maréchal, Françoise, additional, Martis, Antoine, additional, Merabet, Nabiha, additional, Montpellier, Dominique, additional, Moreau, Céline, additional, Musserotte, Emilie, additional, Nouyrigat, Valérie, additional, Oufella, Dalila, additional, Péronnet, Fabrice, additional, Perreau, Jean-Philippe, additional, Planquette, Benjamin, additional, Poiret, Christian, additional, Pottier, Emmanuelle, additional, Prével, Marc, additional, Raphael, Maurice, additional, Raphael, Valérie, additional, Raynaud, Pierre-Joseph, additional, de Revière, Philippe, additional, Ricouard-Bocquet, Sylvie, additional, Riad, Chakib, additional, Riad, Véronique, additional, Jullian, Mireille San, additional, Savoia, Valérie, additional, Simon, Ghislaine, additional, Simon-Libchaber, Esther, additional, Souchet, Catherine, additional, Staikowsky, Frédérik, additional, Sujka, Pascale, additional, Tambon, Michel, additional, Vergnon, Laurent, additional, and Vincelet., Véronique, additional
- Published
- 2015
- Full Text
- View/download PDF
53. Heparin-induced thrombocytopenia leading to a diagnosis of essential thrombocythemia
- Author
-
Marc Bernard, Fabienne Nedelec-Gac, Philippe Mabo, Jessica Valaize, Pierre Gueret, Isabelle Gouin-Thibault, Adeline Pontis, Martin Kerleveo, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Jonchère, Laurent
- Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology ,medicine.medical_specialty ,Clinical Biochemistry ,Inflammation ,030204 cardiovascular system & hematology ,Gastroenterology ,Diagnosis, Differential ,03 medical and health sciences ,0302 clinical medicine ,Polycythemia vera ,Heparin-induced thrombocytopenia ,Internal medicine ,hemic and lymphatic diseases ,medicine ,Humans ,Myelofibrosis ,biology ,business.industry ,Essential thrombocythemia ,Heparin ,Biochemistry (medical) ,Anticoagulants ,food and beverages ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Hematology ,General Medicine ,medicine.disease ,Thrombosis ,Thrombocytopenia ,3. Good health ,[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,030220 oncology & carcinogenesis ,biology.protein ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,medicine.symptom ,business ,Calreticulin ,medicine.drug ,Thrombocythemia, Essential - Abstract
International audience; Essential thrombocythemia (ET) belongs to the “BCR-ABL-negative” subcategory of myeloproliferative neoplasms (MPN) along with polycythemia vera (PV) and primary myelofibrosis (PM). Various recurrent molecular alterations have been described in classical MPN, such as JAK2 V617F, MPL W515L/K mutations, and deletion or insertions in the calreticulin (CALR) gene.1 MPN are known for high incidence of thrombotic complications, with a predominance of arterial rather than venous events (16.2% vs 6.2%). Indeed, the prevalence of overall thrombosis has been described in 28.6%, 20.7%, and 9.5% of patients with PV, ET, and PM, respectively.2 In addition to the traditional risk factors of thrombosis, blood cells count, mutational profile, chronic inflammation, and abnormal cell adhesion appear to be specific risk factors of thrombosis in MPN-patients.3 The classical initial treatment of these thrombotic complications includes unfractionated heparin (UFH).
- Published
- 2021
- Full Text
- View/download PDF
54. The imprecise Dirichlet model.
- Author
-
Jean-Marc Bernard
- Published
- 2009
- Full Text
- View/download PDF
55. Characteristics and clinical outcomes of SARS-CoV-2 infection in adult patients with acute leukemia in France
- Author
-
Pierre-Yves, Dumas, Sarah, Bertoli, Caroline, Bonmati, Martin, Carre, Juliette, Lambert, Mario, Ojeda-Uribe, Sylvain, Chantepie, Franciane, Paul, Eric, Jourdan, Stéphanie, Haiat, Emmanuelle, Tavernier, Pierre, Peterlin, Jean-Pierre, Marolleau, Kamel, Laribi, Corentin, Orvain, Quentin, Cabrera, Pascal, Turlure, Stéphane, Girault, Marie, Balsat, Marc, Bernard, Marie-Christine, Bene, Arnaud, Pigneux, Hervé, Dombret, and Christian, Récher
- Subjects
Adult ,Leukemia, Myeloid, Acute ,Cancer Research ,Oncology ,SARS-CoV-2 ,Acute Disease ,COVID-19 ,Humans ,France ,Hematology - Published
- 2022
- Full Text
- View/download PDF
56. Conventional chemotherapy for acute myeloid leukemia in older adults: Impact on nutritional, cognitive, and functional status
- Author
-
Christian Recher, Eric Jourdan, Anne Banos, Claire Jouzier, Franciane Paul, Bruno Lioure, Romain Guieze, Norbert Ifrah, Pierre-Yves Dumas, Caroline Bonmati, Arnaud Pigneux, Jean-François Hamel, Mathilde Hunault, Jean-Yves Cahn, Jean-Christophe Ianotto, Mario Ojeda-Uribe, Marc Bernard, Norbert Vey, Marie-Christine Béné, Hacene Zerazhi, Jacques Delaunay, Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes (UGA), Centre Hospitalier Universitaire [Grenoble] (CHU), Université d'Angers (UA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CHU Bordeaux [Bordeaux], Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Clermont-Ferrand, Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Strasbourg, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre Hospitalier Emile Muller [Mulhouse] (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), CHU Pontchaillou [Rennes], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre Hospitalier Henri Duffaut (Avignon), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Aix Marseille Université (AMU), Assistance Publique - Hôpitaux de Marseille (APHM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), and Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Male ,Activities of daily living ,MESH: Cognition ,0302 clinical medicine ,Cognition ,MESH: Aged, 80 and over ,Nutritional status ,Activities of Daily Living ,Prospective Studies ,MESH: Geriatric Assessment ,Aged, 80 and over ,MESH: Aged ,Cognitive status ,MESH: Middle Aged ,Myeloid leukemia ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Hematology ,General Medicine ,MESH: Follow-Up Studies ,Middle Aged ,MESH: Nutritional Status ,Leukemia, Myeloid, Acute ,030220 oncology & carcinogenesis ,Older adults ,Cohort ,Toxicity ,Functional status ,Female ,MESH: Leukemia, Myeloid, Acute ,medicine.medical_specialty ,Context (language use) ,Antineoplastic Agents ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,neoplasms ,Aged ,Acute myeloid leukemia ,MESH: Humans ,business.industry ,MESH: Activities of Daily Living ,Geriatric assessment ,MESH: Male ,MESH: Prospective Studies ,MESH: Antineoplastic Agents ,business ,MESH: Female ,030215 immunology ,Follow-Up Studies - Abstract
International audience; Objectives: The impact of conventional treatment for acute myeloid leukemia (AML) on the nutritional, cognitive, and functional status of elderly patients is seldom studied. This assessment was performed in the context of the LAMSA 2007 trial.Methods: The trial enrolled 424 patients with de novo AML. Among them, 316 benefited from geriatric assessment (GA) including nutritional, cognitive, and functional status and were scored according to Eastern Cooperative Oncology Group (ECOG) and sorror for the prediction of treatment toxicity, morbidity, and mortality. Patients were investigated at diagnosis for three times during follow-up.Results: This study showed that AML and its treatment have no impact on cognitive (P = .554) nor functional status (P = .842 for Activity of Daily Living and P = .087 for Instrumental Activities of Daily Living). The nutritional status improved over time (P = .041). None of these three parameters at baseline, associated or not with ECOG and sorror scores, impacted survivals or toxicities.Conclusions: The cognitive, functional, and nutritional status had no impact in this cohort of fit elderly AML patients without unfavorable cytogenetics. The GA tools used provided no additional information compared with ECOG and sorror scores, to predict toxicity, morbidity, or mortality due to intensive chemotherapy.
- Published
- 2021
- Full Text
- View/download PDF
57. Discovering Rules to Design Newspapers: An Inductive Constraint Logic Programming Approach.
- Author
-
Marc Bernard and François Jacquenet
- Published
- 1998
- Full Text
- View/download PDF
58. Free Space Modeling for Placing Rectangles without Overlapping.
- Author
-
Marc Bernard and François Jacquenet
- Published
- 1997
- Full Text
- View/download PDF
59. Preface: Proceedings of the Third International Symposium on Imprecise Probabilities and Their Applications.
- Author
-
Jean-Marc Bernard, Teddy Seidenfeld, and Marco Zaffalon
- Published
- 2003
60. Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial
- Author
-
Norbert Ifrah, Hacene Zerazhi, Pierre-Yves Dumas, Norbert Vey, Isabelle Luquet, Denis Caillot, Marie-Christine Béné, Célestine Simand, Marie-Pierre Ledoux, Véronique Dorvaux, Yosr Hicheri, Anne Banos, Maria Pilar Gallego Hernanz, Chantal Himberlin, Odile Blanchet, Eric Delabesse, Catherine Humbrecht, Pascal Turlure, Arnaud Pigneux, Eric Jourdan, Jacques Delaunay, Didier Bouscary, Emmanuelle Tavernier, Christian Recher, Gaelle Guillerm, Mathilde Hunault-Berger, Romain Guieze, Martin Carre, Anne Bouvier, Jean-Pierre Marolleau, Claude Eric Bulabois, Pascale Cornillet-Lefebvre, Mario Ojeda-Uribe, Marc Bernard, Magda Alexis, Jean-François Hamel, Etienne Daguindau, Pierre Peterlin, Gabrielle Roth Guepin, Emmanuel Gyan, Innate Immunity and Immunotherapy (CRCINA-ÉQUIPE 7), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Hôpital privé du Confluent [Nantes], Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Bordeaux, Service d'Hématologie Clinique et Thérapie Cellulaire, F-33000 Bordeaux, France., Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Cancérologie de Strasbourg Europe (ICANS), Centre hospitalier universitaire de Nantes (CHU Nantes), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire [Grenoble] (CHU), Service d'Hématologie [CHU Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Hôpital Morvan - CHRU de Brest (CHU - BREST ), Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA), Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire de Reims (CHU Reims), Fédérations hospitalo-universitaires Grand Ouest Acute Leukemia [Angers] (FHU GOAL), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service des maladies du sang [Angers], CHU Pontchaillou [Rennes], Département d'Hématologie [CHU Nîmes], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Institut de Cancérologie de la Loire Lucien Neuwirth, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier de la Côte Basque (CHCB), Centre Hospitalier Emile Muller [Mulhouse] (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA), Groupe innovation et ciblage cellulaire (GICC), EA 7501 [2018-...] (GICC EA 7501), Université de Tours (UT), ERL 7001 LNOx (Leukemic Niche & redOx metabolism / Niche leucémique et métabolisme redOx) (LNOx), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Centre National de la Recherche Scientifique (CNRS)-Microenvironnement des niches tumorales (CNRS GDR 3697 Micronit ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Groupe innovation et ciblage cellulaire (GICC), EA 7501 [2018-...] (GICC EA 7501), Université de Tours (UT)-Université de Tours (UT), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional d'Orléans (CHRO), CHU Amiens-Picardie, HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 (HEMATIM), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hématologie clinique et thérapie cellulaire [CHU Limoges], CHU Limoges, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre Hospitalier Henri Duffaut (Avignon), Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Ressources Biologiques [CHU Angers], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], Service d'Hématologie Biologique [Hôpital Robert Debré, Paris], AP-HP Hôpital universitaire Robert-Debré [Paris], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Subjects
Oncology ,Adult ,Male ,Risk ,medicine.medical_specialty ,NPM1 ,Adolescent ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,DNA Mutational Analysis ,Phases of clinical research ,Gene mutation ,Disease-Free Survival ,Cytogenetics ,Young Adult ,Internal medicine ,hemic and lymphatic diseases ,CEBPA ,Medicine ,Cluster Analysis ,Humans ,Chemotherapy ,business.industry ,Gene Expression Regulation, Leukemic ,Gene Expression Profiling ,Remission Induction ,Hematopoietic Stem Cell Transplantation ,Myeloid leukemia ,Hematology ,General Medicine ,Middle Aged ,Prognosis ,Gemtuzumab ,Transplantation ,Leukemia, Myeloid, Acute ,Karyotyping ,Cytogenetic Analysis ,Mutation ,Female ,business - Abstract
International audience; In this randomized phase 3 study, the FILO group tested whether the addition of 6 mg/m(2) of gemtuzumab ozogamycin (GO) to standard chemotherapy could improve outcome of younger patients with de novo acute myeloid leukemia (AML) and intermediate-risk cytogenetics. GO arm was prematurely closed after 254 inclusions because of toxicity. A similar complete remission rate was observed in both arms. Neither event-free survival nor overall survival were improved by GO in younger AML patients (
- Published
- 2021
- Full Text
- View/download PDF
61. Characterisation, Detection and Forecasting of Intra-hourly Wind Power Ramps
- Author
-
Pichault, Mathieu Marc Bernard and Pichault, Mathieu Marc Bernard
- Abstract
One of the challenges preventing greater integration of wind energy into the power grids is the occurrence of large changes in wind power generation over a short amount of time, also called "ramp events". With ever-expanding wind energy penetration, wind power ramps pose a severe risk to electric system security and their mismanagement can have dramatic consequences such as power blackouts. Accurate and timely short-term forecasts are crucial in predicting these ramps and facilitating power grid balancing, storage management, and load dispatch planning. The first part of the thesis is concerned with characterising wind power ramps and their underlying engineering and meteorological processes, with a view to reduce uncertainties in wind power forecasts. It is shown, amongst other things, that 46 % of the ramps at the study site are associated with frontal activity and that wind power fluctuations at the study site tend to plateau before and after the ramps. In the second part of the thesis, two methodologies to predict wind power based on upstream velocity field measurements are introduced and shown to outperform industry benchmarks. The forecasting skill of the proposed methods is particularly evident over the course of wind power ramps, reporting up to 19 % improvement over the persistence benchmark. The opportunities and challenges inherent in using wind LiDARs for ramp forecasting are also discussed. Finally, further analyses of the wind flow fields demonstrate the impact of wind gusts (coherent blocks of strong wind speeds) on ramping behaviour. The results show that wind gusts are associated with increased power variability, both at the wind farm scale and the wind turbine scale. It is also shown that gusts with length scales less than one kilometre tend to travel at the rate of the background flow, whereas larger gusts propagate on average faster. Overall, this research is part of a broader initiative to mitigate greenhouse gas emissions by making wind energy
- Published
- 2021
62. Analog to Digital: Special Care in Dentistry 2015
- Author
-
Ackerman, Marc Bernard
- Published
- 2014
- Full Text
- View/download PDF
63. Indebted to the bank or the profession? New doctor debt and its effect on access to care
- Author
-
Ackerman, Marc Bernard, Waldman, Barry H., and Perlman, Steven
- Published
- 2014
- Full Text
- View/download PDF
64. What is the difference between health and disability?
- Author
-
Ackerman, Marc Bernard
- Published
- 2014
- Full Text
- View/download PDF
65. Why perform a literature review?
- Author
-
Ackerman, Marc Bernard
- Published
- 2014
- Full Text
- View/download PDF
66. Calling all special care dentists: scientific article and case reports wanted!
- Author
-
Ackerman, Marc Bernard
- Published
- 2014
- Full Text
- View/download PDF
67. Acute Care of Older Patients with COVID-19: Clinical Characteristics and Outcomes
- Author
-
Armand Steinmeyer, Marc Bernard, Sara Vienne-Noyes, Sandrine Sourdet, Zara Steinmeyer, Antoine Piau, and Laurent Balardy
- Subjects
Aging ,Pediatrics ,medicine.medical_specialty ,Health (social science) ,Population ,frailty ,lcsh:Geriatrics ,Article ,Malaise ,03 medical and health sciences ,0302 clinical medicine ,Acute care ,medicine ,030212 general & internal medicine ,education ,older adults ,education.field_of_study ,business.industry ,Mortality rate ,COVID-19 ,Retrospective cohort study ,mortality ,lcsh:RC952-954.6 ,Radiological weapon ,Delirium ,Geriatrics and Gerontology ,medicine.symptom ,Complication ,business ,Gerontology ,030217 neurology & neurosurgery - Abstract
(1) Background: COVID-19 has become a global pandemic and older patients present higher mortality rates. However, studies on the characteristics of this population set are limited. The objective of this study is to describe clinical characteristics and outcomes of older patients hospitalized with COVID-19. (2) Methods: This retrospective cohort study was conducted from March to May 2020 and took place in three acute geriatric wards in France. Older patients hospitalized for COVID-19 infections were included. We collected clinical, radiological, and laboratory outcomes. (3) Results: Ninety-four patients were hospitalized and included in the final analysis. Mean age was 85.5 years and 55% were female. Sixty-four (68%) patients were confirmed COVID-19 cases and 30 (32%) were probable. A majority of patients were dependent (77%), 45% were malnourished, and the mean number of comorbidities was high in accordance with the CIRS-G score (12.3 ±, 25.6). The leading causes of hospitalization were fever (30%), dyspnea (28%), and geriatric syndromes (falls, delirium, malaise) (18%). Upon follow-up, 32% presented acute respiratory failure and 30% a geriatric complication. Frailty and geriatric characteristics were not correlated with mortality. Acute respiratory failure (p = 0.03) and lymphopenia (p = 0.02) were significantly associated with mortality. (4) Conclusions: Among older patients hospitalized with COVID-19, clinical presentations were frequently atypical and complications occurred frequently. Frailty and geriatric characteristics were not correlated with mortality.
- Published
- 2020
68. Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial
- Author
-
Vincent Dubée, Pierre-Marie Roy, Bruno Vielle, Elsa Parot-Schinkel, Odile Blanchet, Astrid Darsonval, Caroline Lefeuvre, Chadi Abbara, Sophie Boucher, Edouard Devaud, Olivier Robineau, Patrick Rispal, Thomas Guimard, Emma d’Anglejean, Sylvain Diamantis, Marc-Antoine Custaud, Isabelle Pellier, Alain Mercat, Antoine Brangier, Philippe Codron, Jean Michel Lemée, Virginie Pichon, Robin Dhersin, Geoffrey Urbanski, Christian Lavigne, Roxane Courtois, Hélène Danielou, Jonathan Lebreton, Rémi Vatan, Nicolas Crochette, Jean-Baptiste Lainé, Lucia Perez, Sophie Blanchi, Hikombo Hitoto, Louis Bernard, François Maillot, Sylvain Marchand Adam, Jean-Philippe Talarmin, Emeline Gaigneux, Pauline Motte-Vincent, Marine Morrier, Dominique Merrien, Yves Bleher, Maxime Flori, Amélie Ducet-Boiffard, Orane Colin, Ronan Février, Pauline Thill, Macha Tetart, François Demaeght, Barthelemy Lafond-Desmurs, Maxime Pradier, Agnes Meybeck, Marjorie Picaud, Thierry Prazuck, Guillaume Chapelet, Agnès Rouaud, Paul Le Turnier, Simon Sunder, Aurélien Lorleac'h, Christophe Dollon, Antoine Jacquet, Francois Le Vely, Pierre Gazeau, Séverine Ansart, Hélène Roger, François Laterza, Rodolphe Buzelé, Fella Tahmi, Raphael Lepeule, Karine Lacombe, Bénédicte Lefebvre, Thomas Célarier, Amandine Gagneux-Brunon, Elisabeth Botelho-Nevers, Marc Bernard, Camille Garnier, Morgane Mourguet, Gregory Pugnet, Sara Vienne-Noyes, Guillaume Martin-Blondel, Pierre Delobel, Gaspard Grouteau, Alexa Debard, Laurent Guilleminault, Pauline Arias, Catherine Chakvetadze, Clara Flateau, Aude Kopp, Alain Putot, Jeremy Barben, Suzanne Mouries Martin, Valentine Nuss, Lionel Piroth, Yann-Erick Claessens, Veronique Hentgen, Martin Martinot, Maxime Bach-Bunner, Thomas Bonijoly, Simon Gravier, Jean-Marc Michel, Mathilde Andreu, Mélanie Roriz, Aurélie Baldolli, Julia Brochard, Olivier Grossi, Samuel Pineau, Josselin Brisset, Edouard Desvaux, Guillaume Gondran, Jean-François Faucher, Paul-Antoine Quesnel, Holy Bezanahary, Clément Danthu, Blandine Gutierrez, Kim Ly, Yannick Simonneau, Anne Cypierre, Pauline Pinet, Hélène Durox, Sophie Ducroix-Roubertou, Claire Genet, Guillaume Beraud, Gwenael Le Moal, Blandine Rammaert, Jean-Philippe Lanoix, Claire Andrejak, Cédric Joseph, Sandrine Soriot-Thomas, Robin Dhote, Sébastien Abad, Ruben Benainous, Jean-François Boitiaux, Guillaume Briend, Celine Gonfroy, Stanislas Harent, Aurore Lagrange, Alina Tone, Laura Wayenberg, Sophie Desoutter, Nicolas Ettahar, Thomas Gey, Vincent Leroy, Sacha Gaillard, Andrea Toma, Amaury Broussier, Sandrine Etienne, Yann Spivac, Benoit Martha, Nathalie Roch, Pierre Diaz, Danièle N’guyen Baranoff, Stanislas Rebaudet, François Jourda, Valérie Zeller, Boris Bienvenu, Arnaud Boyer, Marie Briet, Bertrand Guidet, Patrick Mismetti, Eric Vicaut, Olivier Sanchez, Philippe Girard, Antoine Elias, Francis Couturaud, Béatrice Gable, Sybille Lazareff, Loïc Carballido, Catherine Hue, Jean-Marie Chrétien, Adrien Goraguer, Lucie van Eeckhoutte, ATOMycA (CRCINA-ÉQUIPE 6), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Ressources Biologiques [CHU d'Angers] (CRB CHU d'Angers BB-0033-00038), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Département de Pharmacie [CHU d'Angers], Laboratoire de virologie [CHU Angers], Département de Pharmacologie-Toxicologie [CHU Angers], Centre Hospitalier René Dubos [Pontoise], Centre Hospitalier Tourcoing, Service de Médecine Interne [Agen], Centre Hospitalier d'Agen, Centre Hospitalier Départemental Vendée (CHDV), Centre Hospitalier de Versailles André Mignot (CHV), Groupe Hospitalier Sud, Université d'Angers (UA), HYCOVID study group, HYCOVID investigators, Angers University Hospital, Cholet Hospital, Laval Hospital, Le Mans Hospital, Tours University Hospital, Quimper Hospital, La Roche sur Yon Hospital, Tourcoing Hospital, Orléans Hospital, Nantes University Hospital, Niort Hospital, Lorient Hospital, Brest University Hospital, Cherbourg Hospital, Saint-Brieuc Hospital, Créteil – APHP University Hospital, Saint-Antoine – APHP University Hospital, Saint-Etienne University Hospital, Toulouse University Hospital, Melun Hospital, Dijon University Hospital, Princesse Grace – Monaco Hospital, Versailles Hospital, Colmar Hospital, Agen-Nerac Hospital, Caen University Hospital, Saint-Nazaire Hospital, Nantes – Confluent Hospital, Limoges University Hospital, Poitiers University Hospital, Amiens University Hospital, Bobigny – APHP University Hospital, Cergy-Pontoise Hospital, Valencienne Hospital, Valencienne – Clinique Tessier Hospital, Henri-Mondor – APHP University Hospital, Chalon-sur-Saône Hospital, Marseille European Hospital, Auxerre Hospital, Diaconnesses Croix-Saint-Simon Hospital, Marseille – Saint Joseph Hospital, Composition of the HYCOVID management team, Steering committee, Independant data safety and monitoring board, Independent adjudication of clinical events committee, Study management Coordination, Data management., Bernardo, Elizabeth, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Service des maladies infectieuses et tropicales [CHU Angers], and Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC)
- Subjects
0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,030106 microbiology ,Population ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Placebo ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,law ,Interquartile range ,Intensive care ,Internal medicine ,medicine ,Clinical endpoint ,030212 general & internal medicine ,education ,Severe acute respiratory syndrome coronavirus 2 ,education.field_of_study ,Coronavirus disease 2019 ,business.industry ,Hydroxychloroquine ,General Medicine ,Placebo-controlled ,3. Good health ,Infectious Diseases ,Relative risk ,business ,medicine.drug - Abstract
Objectives To determine whether hydroxychloroquine decreases the risk of adverse outcome in patients with mild to moderate coronavirus disease 2019 (COVID-19) at high risk of worsening. Methods We conducted a multicentre randomized double-blind placebo-controlled trial evaluating hydroxychloroquine in COVID-19 patients with at least one of the following risk factors for worsening: need for supplemental oxygen, age ≥75 years, age between 60 and 74 years and presence of at least one co-morbidity. Severely ill patients requiring oxygen therapy >3 L/min or intensive care were excluded. Eligible patients were randomized in a 1:1 ratio to receive either 800 mg hydroxychloroquine on day 0 followed by 400 mg per day for 8 days or a placebo. The primary end point was a composite of death or start of invasive mechanical ventilation within 14 days following randomization. Secondary end points included mortality and clinical evolution at days 14 and 28, and viral shedding at days 5 and 10. Results The trial was stopped after 250 patients were included because of a slowing down of the pandemic in France. The intention-to-treat population comprised 123 and 124 patients in the placebo and hydroxychloroquine groups, respectively. The median age was 77 years (interquartile range 58–86 years) and 151/250 (60.4%) patients required oxygen therapy. The primary end point occurred in 9/124 (7.3%) patients in the hydroxychloroquine group and 8/123 (6.5%) patients in the placebo group (relative risk 1.12; 95% CI 0.45–2.80). The rates of positive SARS-CoV-2 RT-PCR tests at days 5 and 10 were 72.8% (75/103) and 57.1% (52/91) in the hydroxychloroquine group, versus 73.0% (73/100) and 56.6% (47/83) in the placebo group, respectively. No difference was observed between the two groups in any of the other secondary end points. Conclusion In this underpowered trial involving mainly older patients with mild to moderate COVID-19, patients treated with hydroxychloroquine did not experience better clinical or virological outcomes than those receiving the placebo. Trial registration ClinicalTrials.gov Identifier: NCT04325893 ( https://clinicaltrials.gov/ct2/show/NCT04325893 ).
- Published
- 2020
- Full Text
- View/download PDF
69. A Study of Text Summarization Techniques for Generating Meeting Minutes
- Author
-
Marc Bernard, Tu My Doan, François Jacquenet, Christine Largeron, Laboratoire Hubert Curien [Saint Etienne] (LHC), and Institut d'Optique Graduate School (IOGS)-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Multimedia ,Computer science ,business.industry ,Deep learning ,02 engineering and technology ,010501 environmental sciences ,computer.software_genre ,01 natural sciences ,Automatic summarization ,[INFO.INFO-LG]Computer Science [cs]/Machine Learning [cs.LG] ,0202 electrical engineering, electronic engineering, information engineering ,Text generation ,020201 artificial intelligence & image processing ,Artificial intelligence ,business ,computer ,ComputingMilieux_MISCELLANEOUS ,0105 earth and related environmental sciences ,Transformer (machine learning model) - Abstract
A lot of research has been conducted all over the world in the domain of automatic text summarization and more specifically using machine learning techniques. Many state of the art prototypes partially solve this problem so we decided to use some of them to build a tool for automatic generation of meeting minutes. In fact, this was not an easy work and this paper presents various experiments that we did using Deep Learning, GANs and Transformers to achieve this goal as well as dead ends we have encountered during this study. We think providing such a feedback may be useful to other researchers who would like to undertake the same type of work to allow them to know where to go and where not to go.
- Published
- 2020
- Full Text
- View/download PDF
70. Dentistry at crossroads: The access to care crisis for patients with special needs
- Author
-
Ackerman, Marc Bernard
- Published
- 2013
- Full Text
- View/download PDF
71. People with intellectual disabilities must be designated a medically underserved population
- Author
-
Ackerman, Marc Bernard
- Published
- 2013
- Full Text
- View/download PDF
72. First Impressions: How to “Wow” Students into Special Care Dentists
- Author
-
Ackerman, Marc Bernard
- Published
- 2013
- Full Text
- View/download PDF
73. Technology, evidence and the future of Special Care in Dentistry
- Author
-
Ackerman, Marc Bernard
- Published
- 2013
- Full Text
- View/download PDF
74. Retrospective Analysis of the Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin
- Author
-
Philippe Rousselot, Arnaud Pigneux, Juliette Lambert, Denis Caillot, Emmanuel Raffoux, Omar Benbrahim, Sylvain Chantepie, Jean Valère Malfuson, Ollivier Legrand, Caroline Bonmati, Hunault-Berger Mathilde, Anna Berceanu, Lauris Gastaud, Magalie Joris, Sylvie Castaigne, Cécile Pautas, Hervé Dombret, Pierre Peterlin, Marc Bernard, and Sylvie Chevret
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Gemtuzumab ozogamicin ,Immunology ,Myeloid leukemia ,Cell Biology ,Hematology ,Biochemistry ,Internal medicine ,Relapsed refractory ,Retrospective analysis ,Medicine ,business ,medicine.drug - Abstract
Introduction: In 2010 the French Health Agency opened a compassionate patient named program of gemtuzumab ozogamicin (GO, Mylotarg®) in relapsed/refractory (R/R) patients with acute myeloid leukemia (AML). Of note, since 2012, it was recommended to use GO at the dose of 3 or 6 mg/m 2 in addition to chemotherapy. We conducted a retrospective trial (NCT03287128) to evaluate the efficacy and the safety of GO-based regimen in R/R adult AML patients. Patients and methods: We retrospectively collected data of patients older than 18 years treated with GO-based regimen for AML in first relapse or for refractory AML, defined by failure after a prior standard intensive chemotherapy, in 18 French centers between December 15, 2011 and November 10, 2016. The primary objective was to assess the response to GO-based regimen. Patients were considered in response if reaching complete remission (CR), CR without platelet recovery (CRp) or CR with incomplete hematological recovery (CRi). Secondary objectives were the cumulative incidence of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and the safety of the use of GO-based regimen. Results: Three hundred and thirty-five adult patients with R/R AML were included. Median age was 58 years (20 to 80 years). At diagnosis, cytogenetics was favorable in 50 (17%) patients, intermediate in 173 (59%) and adverse in 60 (20%). ELN distribution was favorable: 35%, intermediate: 42% and unfavorable: 23%. NPM1 mutation was present in 29% of patients and FLT3 mutation in 23%. Most patients had de novo AML (84%). Two hundred and thirty-eight patients (79%) were in first relapse and 65 (21%) had a refractory AML. The time between first diagnosis of AML and treatment with GO-based regimen was 4 to 16 months (median 9.4 months). Most patients (88%) received GO in combination with various intensive chemotherapy scheme including "7+3" with anthracycline/cytarabine (n=39 patients), intermediate and high-dose cytarabine (n=68), cytarabine in continuous intravenous infusion (n=78), mitoxantrone/cytarabine (n=49) and fludarabine/cytarabine and/or amsacrine and/or etoposide chemotherapy (n=35). Median follow-up time was 11 months. Among the 305 patients, 191 responded to GO-based regimen: 110 (36%) were in CR, 62 (20%) were in CRp and 19 (6%) in CRi for an overall response rate (CR+CRp+CRi, ORR) of 63%. In multivariate analysis, response was associated with age Regarding safety of GO-based regimen, early deaths occurred within Conclusion. Our study is the first to report efficacy data in the real-world setting of R/R AML adult patients treated with GO-based regimen. In our cohort of 305 patients, response rate was 63% and GO-based regimen appears as a valuable bridge-to-transplant option. Safety analysis showed toxicities consistent with the known safety profile of GO and chemotherapy. Figure 1 Figure 1. Disclosures Lambert: ASTELLAS: Consultancy; CELGENE/BMS: Consultancy. Pautas: PFIZER: Consultancy; ABBVIE: Consultancy. Raffoux: ASTELLAS: Consultancy; PFIZER: Consultancy; ABBVIE: Consultancy; CELGENE/BMS: Consultancy. Legrand: Servier: Consultancy. Gastaud: PFIZER: Consultancy; CELGENE/BMS: Consultancy; ABBVIE: Consultancy; GSK: Consultancy. Pigneux: Amgen: Consultancy; Sunesis: Consultancy, Research Funding; BMS Celgene: Consultancy, Research Funding; Roche: Consultancy, Research Funding; Novartis: Consultancy, Research Funding. Mathilde: SERVIER: Consultancy; ABBVIE: Consultancy. Dombret: Amgen: Honoraria, Research Funding; Incyte: Honoraria, Research Funding; Jazz Pharmaceuticals: Honoraria, Research Funding; Novartis: Research Funding; Pfizer: Honoraria, Research Funding; Servier: Research Funding; Abbvie: Honoraria; BMS-Celgene: Honoraria; Daiichi Sankyo: Honoraria. Rousselot: Incyte, Pfizer: Consultancy, Research Funding. Castaigne: PFIZER: Consultancy.
- Published
- 2021
- Full Text
- View/download PDF
75. Asepsie – Lavage des mains
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
76. Douleur chez l'enfant de moins de 6 ans
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
77. Gaz du sang
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
78. Hémorragie du post-partum précoce
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
79. Échelle canadienne de triage et de gravité pour les départements d'urgence (ETG)
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
80. Solutés d'urgence
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
81. Vaccination – Sérothérapie
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
82. Éclampsie
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
83. Contraception post-coïtale
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
84. Sulfate de magnésium à 15 %
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
85. Isoptine
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
86. Prodilantin
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
87. Brûlures oculaires par produits chimiques
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
88. Asepsie – Préparation du plan de travail en petite traumatologie
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
89. Traumatismes de l'épaule
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
90. Voie veineuse centrale
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
91. Sonde vésicale à demeure chez la femme
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
92. Héparine
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
93. Bacille multirésistant (Patient connu porteur d'un –)
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
94. Détecteur de monoxyde de carbone (CO-testeur)
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
95. Lasilix
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
96. Voie veineuse périphérique pédiatrique
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
97. Classification infirmière des malades d'urgences (CIMU)
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
98. Corps étranger ORL
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
99. Intubation difficile
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
100. Hypertension artérielle
- Author
-
Marc, Bernard, primary, Miroux, Patrick, additional, Piedade, Isabelle, additional, Benveniste, Raphaelle, additional, Jeleff, Charles, additional, and Pateron, Dominique, additional
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.